The Society of Interventional Oncology (SIO) has announced that the first patient has been enrolled in the TRIBUTE trial at the Mayo Clinic in Rochester, USA. The multicentre observational trial will investigate symptomatic high-risk bone metastases treated with percutaneous ablation and palliative radiation therapy. The Mayo Clinic site principal investigators are Brian Welch, Sean Park, and Jonathan Morris.
The TRIBUTE study clinical leadership includes Jack Jennings and Clifford Robinson at Washington University School of Medicine, St. Louis, USA, and Sean Tutton and James Urbanic at University of California, San Diego, USA. “Each new participant brings us closer to understanding how combined percutaneous ablation and palliative radiation can improve outcomes for patients with high-risk bone metastases,” said Jennings. “We look forward to additional sites beginning patient enrolment later this year.”
The TRIBUTE study is collectively supported by the study’s exclusive pioneer trial partner, Varian, a Siemens Healthineers Company, the study’s catalyst trial partner, Stryker, and the study’s advocate trial partner, Boston Scientific.
This is the first prospective, multicentre study to evaluate real-world outcomes (e.g., pain, patient-reported outcomes, skeletal-related events, healthcare utilisation) in adult patients treated with both percutaneous ablation and palliative radiation therapy for symptomatic, high-risk metastatic bone lesions. The study was collaboratively designed and developed with the partnership of radiation oncology, which SIO sees as a critical multidisciplinary partner to the success of the study. Upon completion, the study will enrol 120 subjects from across sites in the USA.
